BIRCHVIEW CAPITAL LP
Q3 2026 Form 13-F
BURLINGTON, VERMONT
CIK 0001618205
· CRD 170534
· SEC-registered investment adviser
$173.1M Reported Value Total
BIRCHVIEW CAPITAL, LP reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $239,112,096, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
13 funds
· $112.3M gross asset value
Hedge Fund: $97.5M · Private Equity Fund: $14.7M
Source: Form ADV filed 2026-10-13
Reported value
$173.1M
Quarter over quarter
-15.4%
Holdings
79
Top-10 concentration
56.0%
Key People
Form ADV owners & control persons
Matthew William Strobeck
CHIEF EXECUTIVE OFFICER AND MANAGING PARTNER
Nicholas Renegar
DIRECTOR OF QUANT STRATEGIES
Benjamin Grant Small
CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 13, 2026 |
| Form | 13F-HR |
| Reported value | $173.1M |
| Positions | 79 |
| Change in reported value | -19.0% |
| New positions | 23 |
| Exited positions | 16 |
| Position turnover | 41.1% |
| Top-10 concentration | 56.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
79 | $173.1M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
72 | $213.8M |
|
Q1 2026 13F
Filed May 15, 2026
|
73 | $175.7M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
68 | $170.8M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
69 | $132.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
71 | $100.7M |
|
Q1 2025 13F
Filed May 15, 2025
|
68 | $115.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
68 | $122.9M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
61 | $115.5M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
60 | $108.2M |
|
Q1 2024 13F
Filed May 14, 2024
|
59 | $122.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
58 | $127.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
51 | $117.7M |
|
Q2 2023 13F
Filed Aug 8, 2023
|
54 | $133.4M |
|
Q1 2023 13F
Filed May 12, 2023
|
55 | $127.7M |
|
Q4 2022 13F
Filed Feb 3, 2023
|
57 | $141.6M |
|
Q3 2022 13F
Filed Nov 7, 2022
|
60 | $142.0M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
60 | $137.5M |
|
Q1 2022 13F
Filed May 13, 2022
|
63 | $138.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
67 | $155.1M |
28 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KLAC KLA CORPORATION | $32.5M | 18.8% |
| 2 | BMY BRISTOL-MYERS SQUIBB CO | $14.0M | 8.08% |
| 3 | LRCX LAM RESEARCH CORPORATION | $9.9M | 5.69% |
| 4 | BDSXXXXX BIODESIX INC | $8.6M | 4.94% |
| 5 | CORT CORCEPT THERAPEUTICS INC | $6.4M | 3.67% |
| 6 | OVV OVINTIV INC | $6.2M | 3.59% |
| 7 | RARE ULTRAGENYX PHARMACEUTICAL INC | $5.6M | 3.24% |
| 8 | SLDB SOLID BIOSCIENCES INC | $5.2M | 2.99% |
| 9 | PTGX PROTAGONIST THERAPEUTICS INC | $4.9M | 2.85% |
| 10 | PRTA PROTHENA CORP PLC | $3.8M | 2.17% |
| 11 | HALO HALOZYME THERAPEUTICS INC | $3.7M | 2.13% |
| 12 | STOK STOKE THERAPEUTICS INC | $3.6M | 2.07% |
| 13 | NBIX NEUROCRINE BIOSCIENCES INC | $3.6M | 2.06% |
| 14 | ACAD ACADIA PHARMACEUTICALS INC | $3.4M | 1.99% |
| 15 | NTLA INTELLIA THERAPEUTICS INC | $3.4M | 1.96% |
| 16 | NKTR NEKTAR THERAPEUTICS | $2.8M | 1.61% |
| 17 | VIR VIR BIOTECHNOLOGY INC | $2.5M | 1.47% |
| 18 | ZBIO ZENAS BIOPHARMA INC | $2.5M | 1.45% |
| 19 | 21217B950 CONTINEUM THERAPEUTICS INC (CTNM) P @ 15.0 01/15/2027 | $2.3M | 1.31% |
| 20 | ABVX ABIVAX SA | $2.1M | 1.2% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.